RNAi-Mediated Silencing of Nuclear Factor Erythroid-2–Related Factor 2 Gene Expression in Non–Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy
- 30 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (19), 7975-7984
- https://doi.org/10.1158/0008-5472.can-08-1401
Abstract
Nuclear factor erythroid-2–related factor 2 (Nrf2) is a redox-sensitive transcription factor that regulates the expression of electrophile and xenobiotic detoxification enzymes and efflux proteins, which confer cytoprotection against oxidative stress and apoptosis in normal cells. Loss of function mutations in the Nrf2 inhibitor, Kelch-like ECH-associated protein (Keap1), results in constitutive activation of Nrf2 function in non–small cell lung cancer. In this study, we show that constitutive activation of Nrf2 in lung cancer cells promotes tumorigenicity and contributes to chemoresistance by up-regulation of glutathione, thioredoxin, and the drug efflux pathways involved in detoxification of electrophiles and broad spectrum of drugs. RNAi-mediated reduction of Nrf2 expression in lung cancer cells induces generation of reactive oxygen species, suppresses tumor growth, and results in increased sensitivity to chemotherapeutic drug–induced cell death in vitro and in vivo. Inhibiting Nrf2 expression using naked siRNA duplexes in combination with carboplatin significantly inhibits tumor growth in a subcutaneous model of lung cancer. Thus, targeting Nrf2 activity in lung cancers, particularly those with Keap1 mutations, could be a promising strategy to inhibit tumor growth and circumvent chemoresistance. [Cancer Res 2008;68(19):7975–84]Other Versions
This publication has 50 references indexed in Scilit:
- Deficiency in Nrf2-GSH Signaling Impairs Type II Cell Growth and Enhances Sensitivity to OxidantsAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-ImidazolideBiochemical and Biophysical Research Communications, 2006
- Glutathione Peroxidase 2, the Major Cigarette Smoke–Inducible Isoform of GPX in Lungs, Is Regulated by Nrf2American Journal of Respiratory Cell and Molecular Biology, 2006
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung CancerPLoS Medicine, 2006
- Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anionArchives of Biochemistry and Biophysics, 2006
- Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cellsOncogene, 2003
- Cisplatin Generates Superoxide Anion by Interaction with DNA in a Cell-Free SystemBiochemical and Biophysical Research Communications, 1994
- Modulation by d,l-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell linesEuropean Journal of Cancer, 1992